Coinfection With SARS-CoV-2, Other Respiratory Pathogens ID’d
Rhinovirus/enterovirus, respiratory syncytial virus, non-SARS-CoV-2 Coronaviridae coinfections detected.
Rhinitis/rhinorrhea (Intranasal Products)
Clinical Guidelines Developed for Managing Nosebleeds
Ongoing active bleeding should be treated with nasal packing; patients should be educated on packing.
FDA to Review Omalizumab for Chronic Rhinosinusitis With Nasal Polyps
The Food and Drug Administration (FDA) has accepted for filing the supplemental Biologics License Application (sBLA) for omalizumab (Genentech) for the treatment of adults with chronic rhinosinusitis with nasal polyps who have had an inadequate response to intranasal corticosteroids. The sBLA includes data from the POLYP 1 and POLYP 2 trials, which showed that treatment…
Are Intranasal Corticosteroids Effective for Non‐Allergic Rhinitis?
Evidence for the effectiveness of intranasal corticosteroids in the management of non-allergic rhinitis appears to be lacking, according to a recently published systematic review.
Positive Results for Xolair in Adults With Chronic Rhinosinusitis with Nasal Polyps
Genentech announced positive topline data from two phase 3 trials, POLYP 1 and POLYP 2, evaluating Xolair (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids.
Ryaltris Safe, Effective for Pediatric Patients in Seasonal Allergic Rhinitis Trial
A new PDUFA date for the treatment is now June 21, 2019; the FDA did not request additional studies from the Company.
Combination Therapy With Azelastine/Fluticasone Superior to Monotherapy in Patients With Allergic Rhinitis
According to the results of a recently published systematic review, the combination of intranasal azelastine plus fluticasone is more effective in reducing symptom scores in patients with allergic rhinitis (AR) than either component alone.
Dupixent sBLA Gets Priority Review for Chronic Rhinosinusitis With Nasal Polyps Indication
Regeneron and Sanofi announced that the Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). The sBLA included data from two phase 3 randomized, double-blind, placebo-controlled trials (SINUS-24…
Dupilumab Effective, Safe in Chronic Rhinosinusitis With Nasal Polyps
Patients with chronic rhinosinusitis with nasal polyps experienced improvements in endoscopic, radiologic, and clinical outcomes when treated with dupilumab as add-on therapy to intranasal mometasone furoate.
Dupilumab Improves QoL in Uncontrolled Asthma and Allergic Rhinitis
Dupilumab is generally well tolerated and improves health-related quality of life associated with rhinoconjunctivitis in patients with uncontrolled moderate to severe asthma with comorbid allergic rhinitis.
